Overview

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

Status:
Completed

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of nab-paclitaxel (Abraxane) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel